Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016673 | 0.89 | MDM4 (0.45) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL30278741 | 0.87 | CASP3 (0.52) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL29855001 | 0.87 | CASP3 (0.52) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL16289027 | 0.87 | CASP3 (0.52) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL15083245 | 0.87 | CASP3 (0.52) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL30055032 | 0.87 | MDM4 (0.48) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL18016107 | 0.86 | MDM4 (0.46) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL24414068 | 0.86 | CASP3 (0.53) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL25182057 | 0.86 | CASP3 (0.53) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL29709555 | 0.86 | CASP3 (0.53) | MDM4TP53KMT2AMDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885KMT2A 14/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885KMT2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.